Lexicon diabetes pill hits endpoint in another phase 3, teeing up regulatory filings by partner Sanofi - FierceBiotech

FierceBiotech

Lexicon diabetes pill hits endpoint in another phase 3, teeing up regulatory filings by partner Sanofi FierceBiotech More patients in the treatment arm hit an established target for glycemic control than did in the control cohort, resulting in Lexicon chalking up its third phase 3 success for the diabetes tablet. The latest trial enrolled 1,402 patients with type 1 ... Lexicon Pharma's sotagliflozin successful in third late-stage diabetes studySeeking Alpha Lexicon Pharmaceuticals Rises on Late-Stage Diabetes Trial24/7 Wall St. all 11 news articles »